PROFIL SUBKLAS IGG PADA INDIVIDU PENERIMA VAKSIN COVID19 PLATFORM VEKTOR VIRUS

Karlina Mahardieni, Jihan Samira, Monica Dwi Hartanti, Sisca Sisca, Yani Kurniawan, Syarif Hidayat

Sari


Respon imun pasca vaksinasi COVID19 beragam dikarenakan proses pembuatan vaksin yang dipercepat untuk mengatasi pandemi COVID19 yang ada. Tujuan penelitian adalah untuk mendapatkan data respon imun seluler individu pasca vaksinasi COVID19 vektor virus sebagai data penunjang kebijakan vaksinasi COVID19 di Indonesia. Metode penelitian yang akan dilaksanakan adalah penggunaan bahan baku tersimpan (BBT) berupa plasma dari individu yang menerima vaksin COVID19 vektor virus yang diambil pada enak titik waktu yang berbeda. Metode Elisa digunakan untuk menilai kadar subklas immunoglobulin G yang ada dalam plasma individu yang menerima vaksinasi COVID19. Uji repeated one-way ANOVA atau Uji Firedman digunakan untuk menganalisa rerata beda kadar subklas IgG pada 4 kelompok berdasarkan waktu. Hasil menunjukkan bahwa subklas IgG1 mendominasi kadar keseluruhan subklas IgG pada keenam titik point waktu.  Terdapat perbedaan yang bermakna kadar IgG1 dan IgG2 berdasarkan waktu (p<0,0001), namun tidak ditemukan perbedaan yang bermakna pada subklas IgG3 (p=0,276) dan IgG4 (p=0,967). Penelitian ini menunjukkan bahwa kadar subklas IgG1 dan IgG2 dapat dijadikan penanda peningkatan imunitas individu penerima vaksin COVID19 vektor virus.


Kata Kunci


vaksin COVID-19; vektor virus, imunitas humoral, subklas IgG

Teks Lengkap:

PDF

Referensi


Akhtar, M., Islam, M. R., Khaton, F., Soltana, U. H., Jafrin, S. A., Rahman, S. I. A., Tauheed, I., Ahmed, T., Khan, I. I., Akter, A., Khan, Z. H., Islam, M. T., Khanam, F., Biswas, P. K., Ahmmed, F., Ahmed, S., Rashid, M. M., Hossain, M. Z., Alam, A. N., Alamgir, A. S. M., … Qadri, F. (2023). Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers in immunology, 14, 1309997. https://doi.org/10.3389/fimmu.2023.1309997

Al-Suhaimi, E. A., Aljafary, M. A., Alkhulaifi, F. M., Aldossary, H. A., Alshammari, T., Al-Qaaneh, A., Aldahhan, R., Alkhalifah, Z., Gaymalov, Z. Z., Shehzad, A., & Homeida, A. M. (2021). Thymus Gland: A Double Edge Sword for Coronaviruses. Vaccines, 9(10), 1119. https://doi.org/10.3390/vaccines9101119

Andualem, H., Kiros, M., Getu, S., & Hailemichael, W. (2020). Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine. ImmunoTargets and therapy, 9, 143–149. https://doi.org/10.2147/ITT.S274746

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E. A., Collins, A. M., Cox, T., Darton, T. C., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K. J., Flaxman, A. L., … Pollard, A. J. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England), 397(10282), 1351–1362. https://doi.org/10.1016/S0140-6736(21)00628-0

Goyins, K. A., Yu, J. J., Papp, S. B., Beddard, R., Murthy, A. K., Chambers, J. P., & Arulanandam, B. P. (2022). Isotyping and quantitation of the humoral immune response to SARS-CoV-2. Experimental biology and medicine (Maywood, N.J.), 247(12), 1055–1060. https://doi.org/10.1177/15353702221084966

Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Kubota-Koketsu, R., Shioda, T., Ono, C., Matsuura, Y., Arase, H., Yoshida, S., Nakamaru, R., Ju, N., Ide, R., Tenma, A., Kawabata, S., Ehara, T., Sakaguchi, M., Tomioka, H., Shimamura, M., Okamoto, S., … Nakagami, H. (2022). Preclinical study of a DNA vaccine targeting SARS-CoV-2. Current research in translational medicine, 70(4), 103348. https://doi.org/10.1016/j.retram.2022.103348

Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus Research, 288. https://doi.org/10.1016/J.VIRUSRES.2020.198114

Kurtović, T., Ravlić, S., Štimac, A., Mateljak Lukačević, S., Hećimović, A., Kazazić, S., & Halassy, B. (2022). Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. Frontiers in immunology, 13, 889736. https://doi.org/10.3389/fimmu.2022.889736

Lazarus, R., Querton, B., Corbic Ramljak, I., Dewasthaly, S., Jaramillo, J. C., Dubischar, K., Krammer, M., Weisova, P., Hochreiter, R., Eder-Lingelbach, S., Taucher, C., Finn, A., Bethune, C., Boffito, M., Bula, M., Burns, F. M., Clark, R., Dasyam, D., Drysdale, S., … Torku, D. (2022). Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV- COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. The Lancet Infectious Diseases, 22(12), 1716–1727. https://doi.org/10.1016/S1473-3099(22)00502-3

Muhoza, P., Danovaro-Holliday, M. C., Diallo, M. S., Murphy, P., Sodha, S. V., Requejo, J. H., & Wallace, A. S. (2021). Routine Vaccination Coverage — Worldwide, 2020. MMWR. Morbidity and Mortality Weekly Report, 70(43), 1495–1500. https://doi.org/10.15585/MMWR.MM7043A1

Reinig, S., Kuo, C., Wu, C. C., Huang, S. Y., Yu, J. S., & Shih, S. R. (2024). Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines. medRxiv : the preprint server for health sciences, 2023.06.16.23291455. https://doi.org/10.1101/2023.06.16.23291455

Stephenson, K. E., Le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., Tostanoski, L. H., Yu, J., Gebre, M. S., Jacob-Dolan, C., Li, Z., Patel, S., Peter, L., Liu, J., Borducchi, E. N., Nkolola, J. P., … Barouch, D. H. (2021). Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA, 325(15), 1535–1544. https://doi.org/10.1001/jama.2021.3645

Ura, T., Okuda, K., & Shimada, M. (2014). Developments in Viral Vector-Based Vaccines. Vaccines, 2(3), 624–641. https://doi.org/10.3390/VACCINES2030624




DOI: https://doi.org/10.33024/jikk.v12i1.16313

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc4.footer##

Pendidikan Dokter Universitas Malahayati Lampung


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.